Ifebemtinib联合garsorasib治疗KRASG12C突变转移性结直肠癌的1b/2期研究
这项在中国七家中心开展的多中心1b/2期研究,评估了口服FAK抑制剂ifebemtinib联合KRASG12C抑制剂garsorasib在经治KRASG12C突变转移性结直肠癌中的疗效与安全性。1b期确定2期推荐剂量为ifebemtinib 100 mg每日一次联合garsorasib 600 mg每日两次;
要点
- 推荐2期剂量为ifebemtinib 100 mg每日一次联合garsorasib 600 mg每日两次。
- 联合治疗3级治疗相关不良事件以腹泻多见,未见4级事件或治疗相关死亡。
核心结论
- ifebemtinib联合garsorasib在经治KRASG12C突变转移性结直肠癌中显示出有前景的抗肿瘤活性和可控的安全性。
- 随机研究中缓解率提高未达统计学显著性,但结果支持在该人群中进一步评估该联合方案。
研究设计与样本
- 多中心1b/2期研究,1b期采用3+3设计评估安全性和耐受性并确定2期推荐剂量。
- 2期包括单臂研究(15例)和开放标签随机研究(36例,1:1随机分配至联合组或garsorasib单药组)。
- 入组患者为年龄≥18岁、组织学确诊局部晚期或转移性KRASG12C突变结直肠癌、ECOG评分0或1、既往含伊立替康或奥沙利铂方案治疗后进展者。
- 2023年4月7日至2024年12月13日共51例患者进入2期;患者均来自中国九家参与中心中的七家,全部为亚洲人。
- 研究注册号NCT06166836和NCT05379946,研究仍在进行但已停止招募。
主要发现
- 单臂研究3级治疗相关不良事件发生于4/15例(27%);随机研究联合组6/18例(33%),单药组5/18例(28%)。
- 联合治疗合并分析中至少2例发生的3级治疗相关不良事件为腹泻6例(18%)、蛋白尿2例(6%)、肠梗阻2例(6%);garsorasib单药组为丙氨酸氨基转移酶升高和γ-谷氨酰转移酶升高各2例(11%)。
关键数值与推荐
- 2期推荐剂量:ifebemtinib 100 mg口服每日一次联合garsorasib 600 mg口服每日两次。
- 2期主要疗效终点为研究者评估的客观缓解率(RECIST 1.1),单臂研究在安全性分析集评估,随机研究在全部随机化患者(意向治疗人群)评估。
- 单臂研究需至少6例客观缓解方可进入随机研究。
临床怎么用
- 对于既往含伊立替康或奥沙利铂方案治疗进展的KRASG12C突变转移性结直肠癌,该联合方案可作为进一步研究方向的参考。
- 联合治疗需关注腹泻、蛋白尿和肠梗阻等3级治疗相关不良事件,以及严重不良事件的发生。
- 随机研究缓解率差异未达统计学显著,暂不支持将其作为标准治疗推荐。
局限性
- 2期样本量小(共51例),随机研究仅36例,置信区间较宽。
- 随机研究为开放标签设计,且未进行分层。
- 全部患者为亚洲人群,结果外推需谨慎。
- 研究仍在进行,尚未报告生存终点数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ifebemtinib is a potent oral focal adhesion kinase inhibitor. Preclinical evidence supports combining ifebemtinib with the KRASG12C inhibitor garsorasib. This study aimed to evaluate this combination in KRASG12C-mutated solid tumours. METHODS: This multicentre, phase 1b/2 study had a phase 1b component to establish the recommended phase 2 dose and a phase 2 multitumour expansion component. In phase 1b, the safety and tolerability of ifebemtinib combined with garsorasib was assessed using a 3 + 3 design in KRASG12C-mutated solid tumours. No dose-limiting toxic effects were observed, and the recommended phase 2 dose was established as ifebemtinib 100 mg orally once daily plus garsorasib 600 mg orally twice daily. Here, we report the results of the cohort of previously treated KRASG12C-mutated metastatic colorectal cancer from phase 2 expansion. Eligible patients (aged ≥18 years) who had histologically confirmed locally advanced or metastatic colorectal cancer harbouring the KRASG12C mutation, an Eastern Cooperative Oncology Group performance-status score of 0 or 1, and had disease progression after previous irinotecan-based or oxaliplatin-based combination therapy, were recruited from seven of nine participating tertiary hospitals in China. On the basis of the recommended phase 2 dose, phase 2 comprised a single-arm study to evaluate the safety and efficacy of ifebemtinib combined with garsorasib and an open-label, randomised study in which patients were randomly assigned (1:1) to receive ifebemtinib plus garsorasib or garsorasib alone, by use of centralised computer-generated block randomisation with no stratification. Investigators were masked to the block size. The primary efficacy endpoint of phase 2 was investigator-assessed objective response rate (Response Evaluation Criteria in Solid Tumours, version 1.1), assessed in the safety analysis set in the single-arm study and in all randomly assigned patients (intention-to-treat population) in the randomised study. At least six objective responses (safety analysis set) were required in the single-arm study to proceed to the randomised study. This study is registered with ClinicalTrials.gov, NCT06166836 and NCT05379946, and is active but not recruiting. FINDINGS: Between April 7, 2023 and Dec 13, 2024, 51 patients were enrolled in phase 2 (15 in the single-arm study and 36 in the randomised study). In the single-arm study, the median age was 53 years (IQR 39 to 63), nine (60%) patients were female, six (40%) were male, and all were Asian. In the randomised study, the median age was 51 years (IQR 42 to 59) in the combination group and 63 years (IQR 54 to 66) in the monotherapy group, 24 (67%) were female, 12 (33%) were male, and all patients were Asian. In the single-arm part, the confirmed objective response rate was 46·7% (95% CI 21·3 to 73·4). Seven patients had partial responses, triggering progression to the randomised study. In the randomised study, the confirmed objective response rate was 38·9% (95% CI 17·3 to 64·3) with the combination therapy versus 16·7% (95% CI 3·6 to 41·4) with garsorasib alone (between-group difference 22·2%, 95% CI -7·7 to 49·1; one-sided p=0·068). In the single-arm study, grade 3 treatment-related adverse events occurred in four (27%) of 15 patients, and in the randomised study, grade 3 treatment-related adverse events occurred in six (33%) of 18 patients in the combination group and five (28%) of 18 in the garsorasib group. Grade 3 treatment-related adverse events occurring in at least two patients were diarrhoea (six [18%]), proteinuria (two [6%]), and intestinal obstruction (two [6%]) in patients treated with combination therapy (combined), and increased alanine aminotransferase and γ-glutamyltransferase (two [11%] each) in patients treated with garsorasib alone. Serious adverse events occurred in ten (30%) patients in the combination group and in four (22%) patients in the monotherapy group. One patient in the garsorasib monotherapy group died due to the underlying malignancy within 30 days after completing study treatment, which was reported as a serious adverse event. The death was assessed by the investigators as not related to garsorasib. No grade 4 treatment-related adverse events or treatment-related deaths were reported across all cohorts. INTERPRETATION: The combination of ifebemtinib and garsorasib showed promising anticancer activity and manageable safety profile in previously treated patients with KRASG12C-mutated metastatic colorectal cancer. Although the improvement in response rate did not reach statistical significance in the randomised study, these findings support further evaluation of ifebemtinib plus garsorasib in this population. FUNDING: InxMed, InventisBio, National Natural Science Foundation of China, the Jian Bing Ling Yan + X Research and Development Program of Zhejiang Province, and the Zhejiang Province Medical and Health Science and Technology Plan Project.
引用
- Song Z, Zhu L, Liu Y, et al. Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial. Lancet Oncol. 2026. PMID: 42636835. doi:10.1016/S1470-2045(26)00175-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。